- Home
- HMN vs ARQT Comparison
HMN vs ARQT Comparison
Compare HMN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMN
- ARQT
- Stock Information
- Founded
- HMN 1945
- ARQT 2016
- Country
- HMN United States
- ARQT United States
- Employees
- HMN N/A
- ARQT N/A
- Industry
- HMN Property-Casualty Insurers
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- HMN Finance
- ARQT Health Care
- Exchange
- HMN Nasdaq
- ARQT Nasdaq
- Market Cap
- HMN 1.8B
- ARQT 1.7B
- IPO Year
- HMN 1991
- ARQT 2020
- Fundamental
- Price
- HMN $45.73
- ARQT $15.52
- Analyst Decision
- HMN Buy
- ARQT Strong Buy
- Analyst Count
- HMN 5
- ARQT 7
- Target Price
- HMN $46.75
- ARQT $19.00
- AVG Volume (30 Days)
- HMN 203.2K
- ARQT 1.7M
- Earning Date
- HMN 08-06-2025
- ARQT 08-06-2025
- Dividend Yield
- HMN 3.04%
- ARQT N/A
- EPS Growth
- HMN 71.62
- ARQT N/A
- EPS
- HMN 3.38
- ARQT N/A
- Revenue
- HMN $1,649,200,000.00
- ARQT $263,464,999.00
- Revenue This Year
- HMN $7.38
- ARQT $72.46
- Revenue Next Year
- HMN $6.25
- ARQT $32.00
- P/E Ratio
- HMN $13.60
- ARQT N/A
- Revenue Growth
- HMN 6.01
- ARQT 99.50
- 52 Week Low
- HMN $33.00
- ARQT $8.03
- 52 Week High
- HMN $46.31
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- HMN 66.07
- ARQT 51.69
- Support Level
- HMN $44.70
- ARQT $13.70
- Resistance Level
- HMN $46.31
- ARQT $15.96
- Average True Range (ATR)
- HMN 0.65
- ARQT 0.70
- MACD
- HMN 0.06
- ARQT -0.06
- Stochastic Oscillator
- HMN 79.32
- ARQT 44.86
About HMN Horace Mann Educators Corporation
Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are 403(b) tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.